Combination therapy for conditions leading to bone loss
US7005413B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 10, 2000 |
| Grant date | Feb 28, 2006 |
| Priority date | — |
| Expiry date | Apr 1, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis. Methods of treatment are described using the polypeptides in conjunction with various agents, including IL-1 inhibitors, TNF-α inhibitors, and serine protease inhibitors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.